Navigation Links
New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
Date:10/17/2008

r meals only if blood glucose levels are elevated. Weight loss with liraglutide is attributed to the fact that it slows gastric emptying and leads to increased satiety after meals. Liraglutide is naturally broken down in the body and does not require renal excretion.

On May 23, 2008, Novo Nordisk submitted a New Drug Application to the Food and Drug Administration in the United States, as well as a marketing authorization application to the European Medicines Agency in Europe, for the approval of liraglutide for the treatment of people with type 2 diabetes. A New Drug Application was also submitted for approval in Japan on July 14, 2008.

About LEAD(TM) (Liraglutide Effect and Action in Diabetes)

LEAD(TM) (Liraglutide Effect and Action in Diabetes) 6 is the first trial to be reported from the phase 3b LEAD(TM) program. Topline results from the LEAD(TM) 6 study were released by Novo Nordisk in a Stock Exchange Announcement on June 6, 2008.

The phase 3a LEAD(TM) program, which comprised the regulatory filing documentation for liraglutide, included trials 1-5. The purpose of the LEAD(TM) program is to compare liraglutide directly against commonly used therapies in type 2 diabetes, except for metformin, with which it is used in combination.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,550 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visi
'/>"/>

SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. Phase III Trial Finds Pharmaxis Bronchitol Effective
7. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
8. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
9. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... Brady (NYSE:BRC), a global leader ... . To align chemical container labeling with OSHA’s updated Hazard Communication (HazCom) Standard ... an example of an accurate label, and pictogram uses and meanings. , “With ...
(Date:7/29/2015)... July 29, 2015  Indivior PLC (LON: INDV) today ... nasal spray was accepted and received Priority Review by ... treatment of opioid overdose. This naloxone nasal spray comes ... for optimal absorption into the nasal mucosa. 1 ... so individuals may be better equipped to help an ...
(Date:7/29/2015)... ... 2015 , ... Finding gooey or crusty material in the corner of your ... considerable number of terms in popular use to describe it, ophthalmologists call it “gound” ... mucus, blood cells, skin cells and dust, but until now there has been virtually ...
(Date:7/29/2015)... ... 2015 , ... Rainbow Scientific, Inc. (RSI), a North American ... BI’s line of human mesenchymal stem cell (hMSC) differentiation media, MSC go ... complete system for multipotency evaluation of hMSCs and reliable induction of hMSCs into ...
Breaking Biology Technology:Brady Announces a New GHS Label Guide 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 4Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 2Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 3
... , , , , , ... -- China,Yongxin Pharmaceuticals, Inc. (OTC Bulletin Board: CYXN; "China ... and,retailer of Chinese traditional medicines, pharmaceutical products, natural,health products, ... The Company today announced that it had opened three ...
... , , REHOVOT, Israel, December ... acute ischemic stroke into its,Phase III clinical study of DP-b99 ... Center, Israel. The MACSI trial involves,numerous medical centers in the ... is D-Pharm,s most advanced product developed,for protection of brain cells ...
... , , HONG KONG, Dec. 31 /PRNewswire-Asia-FirstCall/ -- China Cord ... ), China,s leading provider of cord blood collection, laboratory testing, ... announced that the underwriters of its recent public offering of ... which will result in the issuance of an additional 314,867 ...
Cached Biology Technology:China Yongxin Pharmaceuticals Opened Three New Stores in 2009 and Expanded Customer Base 2China Yongxin Pharmaceuticals Opened Three New Stores in 2009 and Expanded Customer Base 3D-Pharm (TASE: DPRM) Announces Enrollment of First Patient in DP-b99 Phase III Efficacy Study, MACSI 2D-Pharm (TASE: DPRM) Announces Enrollment of First Patient in DP-b99 Phase III Efficacy Study, MACSI 3China Cord Blood Corporation Announces Partial Exercise of Over-Allotment Option 2China Cord Blood Corporation Announces Partial Exercise of Over-Allotment Option 3
(Date:6/30/2015)... YORK , June 30, 2015 To bolster ... security provider HYPR Corp. announced today the addition of two ... will serve as board advisor and David Raviv ... the team underscore HYPR Corp.,s commitment to providing the most ... Dimitri Sirota co-founded Layer 7 Technologies, a provider ...
(Date:6/25/2015)... , June 25, 2015 ... Sensors Market by Type (Swipe & Area), Technology, Material ... Government, Healthcare, Commercial Security & Others) & Geography ... by marketsandmarkets, the said market is expected to ... of 17.1%. Browse 76 market ...
(Date:6/24/2015)... -- This report provides market analysis of the Automatic ... contains an analysis of the drivers, challenges, and restraints ... the short, medium, and long term perspective landscapes. ... technology trends that currently, prevail in the market. It ... efficiently manage the increasing marine traffic and increasing importance ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... common with serial killers? Refined hunting skills, according to a ... Journal of Zoology . A team of US-based researchers ... just like serial criminals. Using the same methods used ... technique usually used to hunt serial criminals, can be used ...
... the University of California, Davis , who discovered a ... a three-year $750,000 grant from the American Asthma , ... asthma, a , chronic disease affecting 300 million people ... study, we propose to evaluate whether the new field ...
... in the flow of the Apalachicola River have far-reaching ... reef fish populations in the northeastern Gulf of Mexico, ... may provide new ammunition for states engaged in a ... found that in years with low river flow, the ...
Cached Biology News:UC Davis grant zeroes in on novel asthma diagnosis and treatment 2UC Davis grant zeroes in on novel asthma diagnosis and treatment 3Troubled waters: Low Apalachicola River flow may hurt gulf fisheries 2Troubled waters: Low Apalachicola River flow may hurt gulf fisheries 3
Ultra Pure Grade. Used in conjunction with IPTG to identify bacterial colonies that contain recombinant plasmids by blue/white selection. X-Gal forms an intense blue precipitate in the presence of be...
Request Info...
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to KLH (Keyhole Limpet Hemocyanin) lysine through amide bonds....
Estrogen Receptor (ER) Competitor Assay Kits Green for Estrogen Receptors-alpha and -beta (ER-Alpha and ER-Beta) are ideal for screening novel estrogen receptor binding compounds and endocrine disrup...
Biology Products: